People taking the highest dose of Mounjaro (tirzepatide) in its landmark clinical trial lost an average of about 21% of their body weight over 72 weeks, roughly one-fifth of their starting weight. At the lowest prescribed dose, the average was closer to 15%. Real-world data from clinics across the United States broadly confirm these numbers, though individual results vary by sex, diabetes status, and how long someone stays on the medication.
What the Pivotal Trial Found, Dose by Dose
The numbers most often cited come from the SURMOUNT-1 trial, a large randomized study of adults with obesity or overweight (without type 2 diabetes) published in the New England Journal of Medicine. At week 72, participants on the 5 mg weekly dose lost an average of 15% of their body weight. Those on 10 mg lost about 19.5%, and those on the highest 15 mg dose lost roughly 21%. The placebo group, by comparison, lost about 3%.1PubMed. Tirzepatide Once Weekly for the Treatment of Obesity
To put those percentages into pounds: for someone starting at 230 pounds, the 5 mg dose would translate to roughly 34 to 35 pounds lost, while the 15 mg dose would mean about 48 pounds. These are averages, so some participants lost considerably more and others less, but even the lowest dose group outperformed what most diet-and-exercise programs achieve over similar time frames.
A separate trial, SURMOUNT-4, used an open-label design where everyone received tirzepatide for 36 weeks before being randomly assigned to continue or switch to placebo. During that initial treatment phase, participants achieved a mean weight reduction of about 21%.2JAMA. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity That 36-week figure is worth noting because it shows substantial weight loss can happen well before the 72-week mark.
How Real-World Results Compare
Clinical trials select participants carefully and monitor them closely, so there is always a question of whether results hold up in everyday practice. The short answer with Mounjaro is that real-world outcomes are surprisingly close to the trial numbers, though slightly lower in some populations.
A retrospective analysis of the Mayo Clinic’s experience found that patients lost an average of about 17% of their total body weight at 12 months. Around 90% of patients lost at least 5%, roughly three-quarters lost at least 10%, and about 40% hit the 20% threshold.3Diabetes. 1707-P: Real-World 12-Month Weight Loss Outcomes of Tirzepatide—The Mayo Clinic Experience Those are striking numbers for a real-world setting where adherence and dose titration aren’t as tightly controlled as in a trial.
A separate U.S. study of people without type 2 diabetes who were new to GLP-1 medications found a mean weight reduction of about 13% at six months. Among those patients, nearly 90% lost at least 5% and about 69% lost at least 10%.4Diabetes & Metabolism. Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States Because this was only a six-month snapshot and many patients were still on lower doses (over half were receiving less than 10 mg), the final numbers would likely have climbed with continued treatment.
For patients with type 2 diabetes, one real-world evaluation of 570 people found a mean reduction of about 7.3 kg (around 16 pounds) in absolute terms.5PubMed. Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus That is lower than what participants without diabetes typically achieve, and the reason comes down to biology.
Why Diabetes Status Makes a Big Difference
Across both the SURPASS trials (for type 2 diabetes) and SURMOUNT trials (for obesity), a consistent pattern emerges: people with type 2 diabetes lose less weight on the same doses. In clinical trials, tirzepatide produced weight loss of up to about 15% in participants with type 2 diabetes compared with up to 21% in those without it, despite similar starting body weights.6Patient Preference and Adherence. The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects
The Mayo Clinic real-world data show the same gap: patients with type 2 diabetes lost about 14% at 12 months compared with about 19% in those without it.3Diabetes. 1707-P: Real-World 12-Month Weight Loss Outcomes of Tirzepatide—The Mayo Clinic Experience The reasons aren’t fully pinned down, but insulin resistance, the metabolic changes that accompany diabetes, and the fact that many diabetes medications promote weight gain all seem to play a role. If you have type 2 diabetes and are starting Mounjaro, a realistic expectation is roughly two-thirds to three-quarters of what the headline trial results show.
Sex, Age, and Other Factors That Shift the Numbers
One of the more interesting recent findings is that sex appears to be a stronger predictor of weight loss on Mounjaro than age. A retrospective study of over 1,000 patients found that women lost significantly more than men after 15 months of treatment: about 15% versus roughly 11%.7PubMed Central. Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis In a related analysis, premenopausal women outperformed postmenopausal women (about 17% versus 14%), hinting that hormonal factors influence the drug’s effectiveness.8Journal of the Endocrine Society. MON-720 Beyond Age: Sex as the Key Weight Loss Predictor with Tirzepatide
Age showed a trend but was not an independent predictor once the researchers adjusted for other variables. In other words, a 65-year-old woman without diabetes could expect results comparable to a 40-year-old woman without diabetes, all else being equal. The factors that independently predicted greater weight loss in multivariable analysis were female sex, absence of type 2 diabetes, no prior use of other obesity medications, not being on weight-gain-promoting drugs (like certain antidepressants or antipsychotics), and being on a higher dose of tirzepatide.7PubMed Central. Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis
That last point about concomitant medications is worth flagging. If you’re taking a medication known to cause weight gain, Mounjaro still works, but it’s pushing against a headwind. Talking to your prescriber about alternatives, where safe, can make a meaningful difference.
The Timeline and When Weight Loss Levels Off
Weight loss on Mounjaro isn’t linear. It accelerates in the first few months as your dose is titrated upward, then gradually decelerates until you reach a plateau. An analysis of the SURMOUNT-1 and SURMOUNT-4 trials examined exactly when that plateau happens. The median time to plateau ranged from about 24 weeks (roughly six months) in people who were overweight but not yet obese, to about 36 weeks (nine months) in those with higher starting BMIs.9PubMed Central. Time to weight plateau with tirzepatide treatment in the SURMOUNT‐1 and SURMOUNT‐4 clinical trials
By week 72, about 88 to 90% of participants across all BMI categories had reached their weight plateau. Higher doses, younger age, and female sex were all associated with a longer time to plateau, meaning the weight kept coming off for a longer stretch. The 15 mg dose extended the plateau by roughly seven weeks compared with the 5 mg dose, which partly explains the larger final weight loss at higher doses.9PubMed Central. Time to weight plateau with tirzepatide treatment in the SURMOUNT‐1 and SURMOUNT‐4 clinical trials
The practical takeaway: if you’re four or five months in and the scale seems to be slowing down, that doesn’t necessarily mean the drug has stopped working. The deceleration is expected, and many people continue to lose weight gradually for several more months, especially at the 10 mg and 15 mg doses. Both medications and biology follow a curve, not a straight line.
How Mounjaro Stacks Up Against Semaglutide
The most common comparison is with semaglutide, the active ingredient in Ozempic and Wegovy. A systematic review and meta-analysis that pooled data from 12 studies found that tirzepatide was associated with about 4.6 percentage points more weight loss and roughly 4.8 kg (about 10.5 pounds) more absolute weight loss than semaglutide.10PubMed. Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis Higher proportions of tirzepatide-treated patients hit every weight-loss benchmark tested. The odds of losing at least 15% of body weight, for example, were nearly three times higher with tirzepatide.
Real-world data echo this gap. A large propensity-matched cohort study found that patients on tirzepatide lost an average of about 14.7% of their body weight versus 10.8% for semaglutide. The proportion achieving at least 15% weight loss in the first year was roughly doubled: about 43% with tirzepatide compared with 22% with semaglutide.11PubMed Central. Weight-loss dynamics with tirzepatide versus semaglutide The monthly rate of weight loss was also faster with tirzepatide.
Both drugs show a nonlinear dose-response pattern, meaning you get diminishing returns as you increase the dose.12PubMed Central. Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis The jump from no medication to the starting dose is the biggest leap; each step up produces a smaller incremental gain. This doesn’t mean higher doses aren’t worth it for many people, but it explains why doubling the dose doesn’t double the result.
What the Weight Loss Is Actually Made Of
A recurring concern with any rapid weight loss, whether from surgery, medication, or severe calorie restriction, is how much of it comes from fat versus lean tissue like muscle. A body-composition sub-study of SURMOUNT-1 found that participants on tirzepatide lost an average of about 34% of their fat mass and 11% of their lean mass over 72 weeks. When translated into the proportion of total weight lost, roughly 75% was fat and 25% was lean mass.13PubMed Central. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight That ratio held in the placebo group too and remained consistent across most subgroups analyzed.
A systematic review confirmed this 75/25 split and noted that the absolute lean-mass loss was relatively modest given the scale of overall weight reduction.14PubMed Central. Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review For context, that ratio is generally considered acceptable in obesity medicine, somewhere between what dietary interventions typically produce and the superior fat-to-lean ratio seen after bariatric surgery. Resistance training during treatment is widely recommended to help preserve muscle, though none of the pivotal Mounjaro trials specifically required it.
Tirzepatide also appears to reduce visceral fat, the metabolically dangerous fat stored around internal organs, more than would be expected from the number on the scale alone. Reductions in waist circumference, a rough proxy for visceral fat, significantly exceeded those seen with placebo across multiple follow-up periods.15PubMed Central. The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies
What Happens When You Stop
This is the question that hangs over every weight-loss medication, and the data on Mounjaro are clear: most people regain weight after stopping. In SURMOUNT-4, participants who had lost about 21% of their body weight during a 36-week treatment phase were randomly assigned to continue tirzepatide or switch to placebo. Over the next year, those switched to placebo regained an average of 14 percentage points, while those who continued lost an additional 5.5%.16PubMed Central. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies
The regain didn’t just affect the number on the scale. A post hoc analysis of that same trial looked at what happened to metabolic health markers across different levels of weight regain. People who regained less than 25% of their lost weight saw essentially no change in waist circumference, cholesterol, or fasting insulin compared with their end-of-treatment values. But those who regained 50% or more saw their blood pressure, cholesterol, insulin levels, and waist circumference rebound substantially.17PubMed Central. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial
The implication is fairly straightforward: for most people, Mounjaro is not a “take it for a year and stop” treatment. The weight loss depends on continued use, similar to how blood pressure medication controls blood pressure only while you’re taking it. Some individuals may be able to step down to a lower maintenance dose, and research into optimal long-term strategies is ongoing, but the current evidence strongly favors continued treatment to maintain results.
The Side Effect Trade-Off
Gastrointestinal symptoms are the most common complaints. An analysis of FDA adverse-event reports found that nausea was reported in about 28% of cases and diarrhea in about 13%.18PubMed Central. Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis Burping and slowed gastric emptying, while less common in absolute numbers, showed the strongest statistical signal compared with other drugs in the database. Most GI side effects occur during dose escalation and tend to ease over several weeks. In the Mayo Clinic cohort, only about 4% of patients discontinued tirzepatide because of side effects.3Diabetes. 1707-P: Real-World 12-Month Weight Loss Outcomes of Tirzepatide—The Mayo Clinic Experience
A practical tip that many prescribers recommend: eat slowly, stick to smaller meals, reduce greasy or very rich foods during the titration phase, and stay well-hydrated. These aren’t just comfort measures. Eating patterns that reduce GI distress tend to improve medication adherence, and adherence is the single biggest determinant of whether someone achieves the weight loss seen in the trials. In the real-world study of people without diabetes, persistence at six months was about 74%.4Diabetes & Metabolism. Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States People who fill prescriptions consistently get results closer to the clinical-trial numbers; those who stop and start or abandon treatment early account for much of the gap between trial and real-world outcomes.
Combining Mounjaro With an Intensive Lifestyle Program
The SURMOUNT-3 trial tested what happens when tirzepatide is layered on top of an intensive lifestyle intervention (structured diet, exercise, and behavioral counseling). Participants first completed a 12-week intensive program, and only those who lost at least 5% of their body weight qualified to continue into the drug phase. Those randomized to tirzepatide then lost an additional 18.4% from their already-reduced weight, while those on placebo actually regained about 2.5%.19PubMed Central. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial Nearly 88% of those on tirzepatide achieved at least an additional 5% weight reduction beyond what they’d already lost through lifestyle change alone.
These results suggest the two approaches are complementary rather than redundant. The lifestyle program produced initial weight loss, and tirzepatide extended it dramatically. For someone motivated enough to commit to a structured program before or during medication use, the total weight loss can exceed what either approach would deliver on its own.
Sleep Apnea and Other Downstream Benefits
Weight loss of the magnitude produced by tirzepatide has effects that go well beyond the scale. Obstructive sleep apnea is one condition where the connection is direct: excess weight, especially around the neck and upper airway, is a primary driver of the disorder, and substantial weight loss often improves or resolves it. Tirzepatide’s potential to improve sleep apnea outcomes has drawn enough clinical interest that a separate body of literature is emerging around the topic.20PubMed Central. Exploring the Effects of Tirzepatide on Obstructive Sleep Apnea: A Literature Review The reductions in visceral fat and waist circumference documented across the SURMOUNT program are the types of changes most strongly linked to sleep apnea improvement.
Other conditions that tend to improve with this degree of weight loss include knee and hip osteoarthritis, nonalcoholic fatty liver disease, and, for people with type 2 diabetes, glycemic control often improves to the point where other diabetes medications can be reduced or eliminated. The SURMOUNT-4 post hoc data showing that metabolic markers stay improved as long as weight regain is limited reinforce the idea that sustaining the weight loss, however it’s achieved, is what drives the health benefits.